Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Clinical Nuclear Medicine|December 6, 2018
Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016Sied Kebir, Manuel Weber, Lazaros Lazaridis, et al.
Cancer Medicine|April 2, 2026
Regrowth Patterns in Glioblastoma-Survival and PredictorsJonas A Feldheim, Jana Grieger, Teresa Schmidt, et al.
Cancers|February 13, 2026
COVID-19 and Influenza Booster Vaccination Elicits Robust Antibody Responses in Patients with Primary Brain Tumors Comparable to Healthy AdultsTeresa Schmidt, Mirko Trilling, Vu Thuy Khanh Le-Trilling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 21, 2014
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PETNorbert Galldiks, Veronika Dunkl, Gabriele Stoffels, et al.
Iscience|January 4, 2024
KDM5B predicts temozolomide-resistant subclones in glioblastomaVivien Ullrich, Sarah Ertmer, Anna Baginska, et al.
Clinical Nuclear Medicine|April 16, 2019
Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed GliomaSied Kebir, Lazaros Lazaridis, Manuel Weber, et al.
Neuro-Oncology Practice|May 14, 2026
End-of-life challenges in neuro-oncological patient care: A survey from the Junge Neuroonkologische ArbeitsgemeinschaftLazaros Lazaridis, Niklas Benedikt Pepper, Paula Klein, et al.
Journal of Neuro-Oncology|January 27, 2021
Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomographySied Kebir, Laurèl Rauschenbach, Manuel Weber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2024
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Data, and Survival DataChristoph Oster, Lukas Kessler, Tobias Blau, et al.
Nature Communications|May 28, 2024
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trialFrank A Giordano, Julian P Layer, Sonia Leonardelli, et al.
Pageof 8